Serum Urate Goals Tied to Lower CV Risk

Patients with gout who reached serum urate targets had modestly higher 5-year cardiovascular event-free survival, with associations strongest among high-risk patients

By
Andrea Surnit
May 11, 2026
4 min

Conexiant

Overview

Achieving guideline-recommended serum urate targets is linked to a lower risk of major adverse cardiovascular events in patients with gout. A study involving over 109,000 patients demonstrated that those reaching urate levels below 6 mg/dL had a significant reduction in cardiovascular events over five years.

Background

Gout is associated with hyperuricaemia, which is recognized as an independent risk factor for cardiovascular disease. The management of serum urate levels is crucial, as achieving target levels can potentially mitigate cardiovascular risks. This study adds to the body of evidence supporting the importance of urate-lowering therapy in reducing cardiovascular events among patients with gout.

Data Highlights

Outcome	Hazard Ratio	Absolute Survival Difference
Major Adverse Cardiovascular Events (Urate < 6 mg/dL)	0.91	~1%
Major Adverse Cardiovascular Events (Urate < 5 mg/dL)	0.77	~3%

Key Findings

27% of patients achieved serum urate levels below 6 mg/dL within 12 months.
80% of those who reached the target did so within 6 months.
Patients achieving serum urate targets had lower risks of myocardial infarction and stroke.
The association was strongest among patients at high or very high baseline cardiovascular risk.
Patients in the treat-to-target group experienced fewer gout flares.

Clinical Implications

Clinicians should prioritize achieving serum urate targets in patients with gout to potentially lower cardiovascular risks. Regular monitoring and adherence to urate-lowering therapy are essential components of effective management.

Conclusion

The findings underscore the importance of serum urate management in patients with gout, suggesting that achieving target levels may contribute to improved cardiovascular outcomes.